SCHEMBL5540892

SCHEMBL5540892

[CH2]c1ccccc1Oc1cc(F)c(F)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.37
HTR2A P28223 2/20 0.37
PARP10 Q53GL7 1/20 0.34
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
ALDH1A1 P00352 4/20 0.32
L3MBTL1 Q9Y468 3/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
HPGD P15428 2/20 0.32
KMT2A Q03164 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
PNLIP P16233 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536030 0.82 CYP1A2 (0.40) SLC6A4HTR2AALDH1A1L3MBTL1MAPK1
SCHEMBL5537197 0.79 ALDH1A1 (0.51) SLC6A4HTR2AMAPTALDH1A1HPGD
SCHEMBL3755349 0.78 ALDH1A1 (0.49) SLC6A4HTR2APARP10MAPTALDH1A1
SCHEMBL5541162 0.75 HTR1A (0.46) SLC6A4PARP10KDM4EALDH1A1L3MBTL1
SCHEMBL5536181 0.75 HTR2A (0.46) SLC6A4HTR2APARP10MAPTALDH1A1
SCHEMBL95189 0.74 LTA4H (0.52) SLC6A4ALDH1A1L3MBTL1MAPK1HTT
SCHEMBL5540267 0.74 ALDH1A1 (0.47) SLC6A4ALDH1A1L3MBTL1MAPK1HTT
SCHEMBL5540384 0.74 NPSR1 (0.56) SLC6A4HTR2AMAPTALDH1A1L3MBTL1
SCHEMBL5540166 0.74 SLC6A2 (0.42) SLC6A4PNLIPSLC6A2SLC6A3
SCHEMBL7634253 0.73 CA1 (0.38) MAPTKDM4ECRHBPCRHR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SLC6A4 4191/4885HTR2A 4120/4885PARP10 4531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.